

*Annual Board Review and Update in  
Pulmonary and Critical Care Medicine course*

***Management of the Chronic Respiratory  
Failure Patient***

Miguel Divo, MD, MPH

Pulmonary, Critical Care Division

Co-Director Respiratory Services SRH-C

Brigham and Women's Hospital

Harvard Medical School




# Conflict of Interest Disclosure

I have no financial relationships with commercial entities producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.

# Objectives

1. Epidemiology of the Chronic Respiratory Failure
2. Pathophysiology of respiratory failure
3. Methods used to liberate from prolonged mechanical ventilation
4. Outcomes


# Mechanical Ventilation Multicenter Prevalence Study



Esteban A et al. *JAMA*. 287(3):345-355, 2002.

Esteban A et al, *Am J Respir Crit Care Med*.161(5):1450-8, 2000

# How Big is the Problem?



Esteban A., et al.. N Engl J Med 1995;332:345-50. 63.

Brochard L., et al.. Am J Respir Crit Care Med 1994;150:896-903.

# PMV are not created equal



Neuromuscular diseases

Reversible


Irreversible

Chronically Critically ill  
Debilitated Patient  
Survivor of a  
Catastrophic Event


Post-surgical

Medical


# Medical diagnoses resulting in PMV: 61%



# Surgical diagnoses resulting in PMV: 39%




# The Epidemiology of Chronic Critical Illness in the United States\*



*Khan et al, Crit Care Med 2015; 43:282–287*

# The Epidemiology of Chronic Critical Illness in the United States\*



*Khan et al, Crit Care Med 2015; 43:282–287*

# Learning Points 1


1. Chronic respiratory failure patients are the product of our own medical advances and success
2. Affect mostly the elderly, however genetic, trauma, overdose affect mostly young individuals
3. Up to 20-30% of our ICU patients meet criteria of prolonged MV

# Objectives



1. Epidemiology of the Chronic Respiratory Failure
2. Pathophysiology of respiratory failure
3. Methods used to liberate from prolonged mechanical ventilation
4. Outcomes

# Respiratory Failure


Ventilatory Pump: PaCO<sub>2</sub>



Gas Exchange: PaO<sub>2</sub>



# Hypercapnic Respiratory Failure




$$PaCO_2 = \frac{VCO_2}{VA}$$




$$VA = (RR * Vt) \left(1 - \frac{Vd}{Vt}\right)$$

# Determinant of fatigue


Task to be performed 24 X 7 X lifetime



# The magic of “rehab”




# Increase Capacity: it takes a village!




RT+ PT+ OT+ SLP+ RN= Superpower

# Can we decrease the load?



# Setbacks....


Setbacks (including us)



CCI Patient

Odds of surviving

# The 7 plagues: Deviation from the recovery process



# Learning Points 2

1. Weaning is not just the mere action of removing the ventilator
2. Weaning is the systematic evaluation for the causes leading to respiratory failure and reverse them (if possible)

# Objectives

1. Epidemiology of the Chronic Respiratory Failure
2. Pathophysiology of respiratory failure
3. Methods used to liberate from prolonged mechanical ventilation
4. Outcomes

# Post-ICU Weaning Strategies

<u>Study</u>	<u>Decreasing Support</u>	<u>Increasing SBT</u>
• Gracey ' 98	SIMV/PSV	TTO
• Petrak ' 98	ACV	VTM, PSV
• Bagley ' 97	-----	VTM/TP
• Clark ' 97	PSV	VTM/TP
• Latriano '96	SIMV/PSV	VTM/TP
• Scheinhorn ' 94	SIMV/PSV	VTM

TTO= transtrach O2; VTM= Venturi mask; TP= T piece

# TIPS protocol for weaning patients from PMV

TIPS <sup>®</sup> Protocol	WEANING STEPS
<p><b>INITIAL VENTILATOR SETTING</b>                      For initial flow/volume setting, see footnote a                      For patient admitted on SIMV/PS:                      If SIMV &gt;10 or PSV ≥ 20 → change to A/C                      If SIMV ≤10 and PSV ≤ 20 → no change but begin TIPS with footnote b or footnote c</p>	<p><b>Reduction of SIMV</b></p> <ol style="list-style-type: none"> <li>1. SIMV 10 / PS 20 (footnote e)</li> <li>2. SIMV 8 / PS 20</li> <li>3. SIMV 6 / PS 20</li> <li>4. SIMV 4 / PS 20</li> </ol>
<p><b>DAILY EVALUATION (DE)</b>                      Do NOT wean if any ONE is present:</p> <ol style="list-style-type: none"> <li>1. Hemodynamic instability:                             <ul style="list-style-type: none"> <li>• Dopamine infusion &gt;5 mcg/kg/min</li> <li>• Systolic blood pressure &lt; 90 mmHg</li> <li>• Pulse &lt; 50 or &gt; 130 bpm</li> </ul> </li> <li>2. Temp &gt;100.4</li> <li>3. FIO<sub>2</sub> &gt; 0.5 or PEEP &gt; 8</li> <li>4. Other (record reason)</li> </ol>	<p><b>Reduction of PSV</b></p> <ol style="list-style-type: none"> <li>5. SIMV 4 / PS 18</li> <li>6. SIMV 4 / PS 16</li> <li>7. SIMV 4 / PS 14</li> <li>8. SIMV 4 / PS 12</li> <li>9. SIMV 4 / PS 10</li> </ol>
<p><b>WEANING ASSESSMENT (WA)</b>                      Do NOT wean if any ONE is present:</p> <ul style="list-style-type: none"> <li>Respiratory rate &gt; 35</li> <li>Spontaneous tidal volume &lt; 0.3 L</li> <li>O<sub>2</sub> saturation &lt; 90%</li> <li>Pulse &gt; 130 or increase from baseline &gt; 20</li> <li>5. Prominent accessory muscle use</li> </ul>	<p><b>SBTs (footnotes d &amp; e)</b></p> <ol style="list-style-type: none"> <li>10. 1 hour</li> <li>11. 2 hours (draw ABG, result to MD)</li> <li>12. 4 hours</li> <li>13. 6 hours</li> <li>14. 8 hours</li> <li>15. 10 hours</li> <li>16. 12 hours</li> <li>17. 16 hours (footnote f)</li> <li>18. 20 hours</li> <li>19. 24 hours</li> </ol>
<p>Do RSBI after first successful WA; if RSBI ≤ 80 start weaning at Step 10</p>	<p><b>Footnotes</b></p> <p>a) Set flow rate between 70 and 100, decelerating flow. Set Vr to 9ml/kg up to 900ml. If plateau pressure &gt; 35, titrate tidal volume downward to 7ml/kg.</p>
<p><b>WEANING</b></p> <ol style="list-style-type: none"> <li>1. Chart baseline WA, then advance TIPS step.</li> </ol>	<p>may be continued one more step.                      f) Add EKG telemetry when SBT is to extend beyond 10 p.m.</p>

Daily Evaluation

Weaning Assessment


Gradual Reduction SIMV Rate

Gradual Reduction PSV

Gradual Increments SBTs


Faster Weaning: from 39 to 17 Days  
 Decreases variability of weaning practices

# PSV or T-mask?




Jubran A, et al. *JAMA* 2013;309:671–677.

# How to choose?



# Weaning Strategy Highway




# Objectives

1. Epidemiology of the Chronic Respiratory Failure
2. Pathophysiology of respiratory failure
3. Methods used to liberate from prolonged mechanical ventilation
4. Outcomes


# Mapping the mechanical ventilation weaning process

Admission




Time ... (LOS)

# Mapping the mechanical ventilation weaning process



# Reality: One year survival rate



Gracey DR, et al, CHEST 1995; 107:494-499  
Carson SS, et al AJRCCM 1999; 159:1568-1573  
Scheinhorn D, et al, CHEST 2007

Scheinhorn DJ, et al, CHEST 1997; 111:1654-1659  
Nasraway SA, et al CCM 2000; 28: 19-25  
Stoler J, et al, 2003; 124: 1892-1899

# Conclusions

- Weaning is a collaborative process
- Physician should identify and when possible, treat reversible causes of weaning failure
- Weaning is more than the transfer of effort from the machine to the patient
- Para-medical personnel are the key to make the plan work
- More research and multi-specialty collaboration is needed

# Question

- A 73 y/o patient is admitted to LTACH from the ICU, on mechanical ventilation via tracheostomy tube. Patient failed extubation attempt in the ICU, thus the decision for tracheostomy. The reason for his ICU admission was COVID-19 ARDS.
- Upon arrival patient passed screening for SBT, and was placed on trach-mask for 45 min and resulted: RSBI 145, RR 36 BPM and O2 sat 94%

# Question

Based on the SBT results, should this patient be :

- A. Initiate weaning plan on SIMV-PS with incremental increase in SIMV
- B. Incremental T-mask trials
- C. PSV trials with incremental time and sequential decrease in PS
- D. Deem the patient as unweanable

# Answer

Based on the SBT results, should this patient be :


A. Initiate weaning plan on SIMV-PS with incremental increase in SIMV

B. Incremental T-mask trials

**C. PSV trials with incremental time and sequential decrease in PS**

D. Deem the patient as unweanable

# Answer: PSV



Jubran A, et al. *JAMA* 2013;309:671–677.